Observational Study About Patients Diagnosed With NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Inclusion Criteria:1. patients diagnosed with nonalcoholic fatty liver diseaseExclusion Criteria:patients suspected of excessive alcohol consumptionmalignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigationincomplete data such as HBV serological results and abdominal ultrasound resultspatients who refuse to sign informed consent